RT Journal Article
SR Electronic
T1 Long-term outcome of corneal collagen crosslinking with riboflavin and UV-A irradiation for keratoconus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.05.22270507
DO 10.1101/2022.02.05.22270507
A1 Seifert, Franziska K.
A1 Theuersbacher, Johanna
A1 Schwabe, Dorothee
A1 Lamm, Olga S.
A1 Hillenkamp, Jost
A1 Kampik, Daniel
YR 2022
UL http://medrxiv.org/content/early/2022/02/08/2022.02.05.22270507.abstract
AB Purpose To evaluate long-term outcomes of corneal collagen crosslinking (CXL) using riboflavin and UV-A irradiation and to determine when to repeat CXL.Methods In this retrospective consecutive interventional case series 131 eyes of 131 patients (95 male, 36 female, mean age 29.7±11.4 years) between 2006 and 2016 received standard CXL (Dresden protocol, epithelium-off) for progressive keratoconus. Corrected distance visual acuity (CDVA) and corneal tomography (K1, K2, Kmax) were repeatedly recorded 1 year (n=103 eyes) to 10 years (n=44) postoperatively. Only one eye per patient was included. Paired t-test or Wilcoxon matched-pairs signed rank test was used for parametric and nonparametric data, respectively.Results 1 to 3 years preoperatively, median K2 significantly increased by 1.1D (p<0.001). Postoperatively, median K2 increased by 0.1D after 1 year, then decreased over the remaining postoperative period by 0.85D (p=0.021). Median apical corneal thickness decreased by 16µm (p=0.012) after 5 years and then returned to preoperative values. Mean CDVA showed a significant improvement (decrease in logMAR 0.12 after 10 years, p=0.010). Kmax fluctuated without significant change. CXL non-responders, defined by a postoperative increase in Kmax>2D, increased from 16% after 5 to 33% after 10 years. Risk factors for non-response were young age, high astigmatism, thin cornea, and atopic dermatitis. 4 eyes were re-treated 3–4 years after first CXL without complications and keratoconus stabilized thereafter.Conclusions CXL can slow or stop keratoconus progression. However, as the number of responders declines after 5 years, patients with risk factors may require re-treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by internal funds of the Department of Ophthalmology, University Hospitals Wuerzburg.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the medical faculty of the University of Wuerzburg gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.